Navigation Links
Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
Date:1/13/2009

f narcolepsy with cataplexy in adult patients. Most commonly reported adverse drug reactions in narcolepsy patients are dizziness, nausea and headaches. Sodium oxybate has the potential to induce respiratory depression and neuropsychiatric events. Sodium oxybate has not been evaluated by regulators for the treatment of fibromyalgia and is not approved for this use.

About Fibromyalgia

Fibromyalgia, a chronic condition characterized by widespread pain, affects 0.5% - 5% of adults worldwide. Fibromyalgia is believed to be a central nervous system condition, resulting from neurological changes in how the brain perceives and responds to pain. In addition to pain, the main symptoms are fatigue, disturbed sleep and morning stiffness. The exact causes of fibromyalgia are unknown. It may be triggered by physical trauma, emotional stress, chronic pain or infection. Genetics, neurochemicals that affect pain modulation, neurohormones and sleep physiology abnormalities are thought to play a role. Research also has suggested a relationship between sleep and pain. Fibromyalgia patients experience a high prevalence of sleep problems, including a reduction in non-restorative or deep sleep.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. The Company has an unwavering commitment to improving care for patients with serious psychiatric and neurological conditions through innovative treatments and distinctive and valuable programs for patients and physicians. For further information see http://www.JazzPharmaceuticals.com.

Jazz Pharmaceuticals "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... MARLBOROUGH, Mass. , May 1, 2015  Boston ... overview of its continued business momentum and long-term growth ... in New York City . President ... outline the unique opportunities the company has to bring ... into fast growing markets and deliver shareholder value. ...
(Date:5/1/2015)... May 1, 2015 Cambrex Corporation (NYSE: CBM ... 2015. Highlights , Sales increased ... 27% excluding foreign currency impact, driven by Innovator products and ... $8.4 million in the first quarter of 2014. , ... in the first quarter last year and Adjusted Diluted EPS ...
(Date:4/30/2015)... Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its first quarter ended March 31, ... quarter of 2015 was $116.2 million, up $14.5 million ... down $5.3 million or 4.4% from the fourth quarter ... as reported in accordance with U.S. generally accepted accounting ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20
... Inc. (Nasdaq: MYL ) today announced that ... from the U.S. Food and Drug Administration (FDA) for ... Tablets, 150mg. This product is the generic version of ... prevention of osteoporosis in postmenopausal women. Boniva® ...
... 2012 SARC, Sarcoma Alliance for Research through Collaboration, ... Tuesday, March 20, 2012, the U.S. Food and Drug ... two New Drug Applications submitted by two pharmaceutical companies ... the treatment of sarcoma.  Sarcoma is a rare cancer ...
Cached Medicine Technology:FDA's Oncologic Drugs Advisory Committee to Review Two New Drug Applications for Sarcoma on Tuesday, March 20, 2012 2
(Date:5/3/2015)... (PRWEB) May 03, 2015 " Bubbly Walrus ... AppWatch, which takes a look at the latest and coolest ... Toohey, the host of AppWatch and technology expert, conducted the ... entertaining and educational game. , The best games to play ... think. Instead of users killing brain cells with a video ...
(Date:5/3/2015)... 2015 Looking for a graduate ... impact your career? The Master of International Business, ... in multinational companies and for professionals seeking a ... global landscape, differences in culture, religion, government, and ... program develops the global competence and confidence needed ...
(Date:5/3/2015)... It is not too late to register to take ... of Lissa Anne Been in Arnold, Missouri on May 9, ... to honor her loving memory. It has benefited the renowned Brain ... turned 37, Lissa suffered a brain aneurysm . After two ... This event is designed to serve as a remembrance of her ...
(Date:5/2/2015)... 2015 Ticket Down has secured additional inventories ... long awaited event today, Saturday, May 2nd at the MGM ... will be able to secure tickets for both the actual ... boxing fans have wanted for more than five years was ... Mayweather will step inside the ring to fight Manny “Pac-Man” ...
(Date:5/2/2015)... ProText Kinetic 2 is a set of typography ... X. ProText Kinetic 2 features 40 animation presets ... X . Easily create interactive text videos without having ... Kinetic 2. , Using ProText Kinetic is as easy as ... presets in the FCPX timeline. Playback the default animation ...
Breaking Medicine News(10 mins):Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2
... is helping to increase understanding about normal vaginal biology ... women prone to infections and other diseases, and ... suffer from insidious health problems, including bacterial vaginosis and ... to seek medical treatment, said Larry Forney, a professor ...
... times as much food as conventional farming on the ... refute the long-standing assumption that organic farming methods cannot ... ,Researchers from the University of Michigan found that ... and conventional farms. In developing countries, food production could ...
... found that children with Tourettes syndromean inherited neurological disorder ... learn certain mental grammar skills much faster than their ... at Georgetown University Medical Center and the Kennedy Krieger ... linked to tics in Tourettes syndrome may also result ...
... of Havana have found that two compounds from lobster ... properties. ,The researchers said that the compounds could ... and antiseptic properties, as well as to increase growth ... a very common polymer present in nature as part ...
... Laboratories announced primary results for its large-scale clinical ... non-hormonal, non-prescription Zestra(R) Feminine Arousal Fluid for ... study, designed and managed by David M. Ferguson, ... parallel design trial intended to expand on the ...
... day, the Australian police finally announced that the Dr.Mohammed ... charged with providing reckless support to terrorists by ... ,His cousin Sabeel Ahmed 26, who worked at Halton ... of having information that could have helped police prevent ...
Cached Medicine News:Health News:Vaginal Bacteria Vary Among Healthy Women 2Health News:Organic Farming Can Feed the World 2Health News:Organic Farming Can Feed the World 3Health News:Tourettes Syndrome in Children may also Result in Superior Learning Skills 2Health News:Lobster Shells Have Great Healing and Antiseptic Properties 2Health News:Study Shows Positive Results for Zestra(R) Feminine Arousal Fluid 2Health News:Three Doctors Charged So Far in the UK Bombing Case 2Health News:Three Doctors Charged So Far in the UK Bombing Case 3Health News:Three Doctors Charged So Far in the UK Bombing Case 4
Human based material available in two levels for thecontrol of percision for up to 10 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Medicine Products: